Cargando…

Effect of Concomitant Use of Analgesics on Prognosis in Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

BACKGROUND: Drug–drug interactions (DDIs) pose new challenges beyond traditional pharmacodynamics in the context of optimizing the treatment options with immune checkpoint inhibitors (ICIs). To alleviate cancer-related pain, analgesics are of absolute vital importance as chronic medications used by...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mao, Ziyang, Jia, Xiaohui, Jiang, Panpan, Wang, Qinyang, Zhang, Yajuan, Li, Yanlin, Fu, Xiaolan, Jiao, Min, Jiang, Lili, Liu, Zhiyan, Guo, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120587/ https://www.ncbi.nlm.nih.gov/pubmed/35603146 http://dx.doi.org/10.3389/fimmu.2022.861723

Ejemplares similares

First‐line immune‐based combination therapies for advanced non‐small cell lung cancer: A Bayesian network meta‐analysis
por: Mao, Ziyang, et al.
Publicado: (2021)

Eosinophil as a biomarker for diagnosis, prediction, and prognosis evaluation of severe checkpoint inhibitor pneumonitis
por: Li, Yanlin, et al.
Publicado: (2022)

Characteristics of the immunogenicity and tumor immune microenvironment in HER2-amplified lung adenocarcinoma
por: Wang, Qinyang, et al.
Publicado: (2022)

Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis
por: Li, Yanlin, et al.
Publicado: (2023)

Impact of concomitant medications on the efficacy of immune checkpoint inhibitors: an umbrella review
por: Li, Honglin, et al.
Publicado: (2023)

An Indirect Comparison Between Nivolumab + Ipilimumab + Two Cycles of Chemotherapy vs. Pembrolizumab + Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer
por: Jiang, Panpan, et al.
Publicado: (2021)

Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors
por: Xu, Shuo, et al.
Publicado: (2021)

A genomic instability-related lncRNA model for predicting prognosis and immune checkpoint inhibitor efficacy in breast cancer
por: Jiao, Ying, et al.
Publicado: (2022)

Advances in immune checkpoint inhibitors induced-cardiotoxicity
por: Li, Xiang, et al.
Publicado: (2023)

On the Road to Immunotherapy—Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies
por: Ward, Frank J., et al.
Publicado: (2018)

Fatty Acid Metabolic Signaling Pathway Alternation Predict Prognosis of Immune Checkpoint Inhibitors in Glioblastoma
por: Liu, Rongrong, et al.
Publicado: (2022)

The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors
por: Zhang, Lilong, et al.
Publicado: (2022)

Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer
por: Zou, Xue-lin, et al.
Publicado: (2021)

TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments
por: Liao, Ping, et al.
Publicado: (2023)

Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors
por: Hu, Xiangxiao, et al.
Publicado: (2023)

Neutrophil to Lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
por: Zhang, Wei, et al.
Publicado: (2023)

CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors
por: Chen, Yu, et al.
Publicado: (2020)

TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy
por: Qiu, Hui, et al.
Publicado: (2021)

Concomitant Statins and the Survival of Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Meta-Analysis
por: Zhang, Lei, et al.
Publicado: (2022)

The causal relationship between gut microbiota and inflammatory dermatoses: a Mendelian randomization study
por: Mao, Rui, et al.
Publicado: (2023)

Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy
por: Johansen, Astrid Z., et al.
Publicado: (2023)

The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors
por: Zhou, Jiaxin, et al.
Publicado: (2022)

Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors
por: Zhang, Lilong, et al.
Publicado: (2023)

Peripheral cytokine levels as novel predictors of survival in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
por: Mao, Xin-Cheng, et al.
Publicado: (2022)

Effects of Concomitant Antibiotics Use on Immune Checkpoint Inhibitor Efficacy in Cancer Patients
por: Jiang, Shuai, et al.
Publicado: (2022)

Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors
por: Ancel, Julien, et al.
Publicado: (2023)

Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis
por: Westdorp, Harm, et al.
Publicado: (2021)

Editorial: The Roles of Checkpoint Inhibitors in Inflammatory Diseases
por: von Knethen, Andreas, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Human Glioma Microenvironment
por: Ghouzlani, Amina, et al.
Publicado: (2021)

Cutaneous manifestations associated with immune checkpoint inhibitors
por: Watanabe, Tomoya, et al.
Publicado: (2023)

Biomarkers of related driver genes predict anti-tumor efficacy of immune checkpoint inhibitors
por: Jiang, Shuai, et al.
Publicado: (2022)

CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
por: Han, Rui, et al.
Publicado: (2023)

Unsatisfied Reporting Quality of Clinical Trials Evaluating Immune Checkpoint Inhibitor Therapy in Cancer
por: Chen, Chen, et al.
Publicado: (2021)

Diversity of Dominant Peripheral T Cell Receptor Clone and Soluble Immune Checkpoint Proteins Associated With Clinical Outcomes Following Immune Checkpoint Inhibitor Treatment in Advanced Cancers
por: Li, Ye, et al.
Publicado: (2021)

Efficacy of Immune Checkpoint Inhibitors in Patients With EGFR Mutated NSCLC and Potential Risk Factors Associated With Prognosis: A Single Institution Experience
por: Bai, Menglin, et al.
Publicado: (2022)

A Whole Exon Screening-Based Score Model Predicts Prognosis and Immune Checkpoint Inhibitor Therapy Effects in Low-Grade Glioma
por: Luo, Cheng, et al.
Publicado: (2022)

The immune checkpoint VISTA is associated with prognosis in patients with malignant uveal melanoma
por: Issam Salah, Nour el Imane, et al.
Publicado: (2023)

Effect of renin-angiotensin-aldosterone system inhibitors on survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
por: Shen, Jinhai, et al.
Publicado: (2023)

Concomitant Medication Effects on Immune Checkpoint Inhibitor Efficacy and Toxicity
por: Sieber, Brendan, et al.
Publicado: (2022)

Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
por: Jiang, Jingyu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p119lvm97sscvvhop27lmjndd0